drugset / Trial / NCT02592356

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

NCT02592356

NaSingle-groupOpen-labelSupportive care

Summary

The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.

Timeline

Start
2015-11-16
Primary completion
2024-03-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Background Cabozantinib Small molecule
Background Lenvatinib Small molecule